Skip to main content
. 2019 Aug 22;5:14. doi: 10.1186/s40959-019-0046-5

Table 3.

Cancer diagnosis/type, chemotherapy agent class and radiation therapy (Medical Record Review cohort only)

N = 46 Mean (range) n (%)
Cancer diagnosis
 Age at first cancer diagnosis (years) 53.6 (6.3–89.3) 46 (100)
  Bile duct 1 (2)
  Breast 14 (30)
  Colon 1 (2)
  Hodgkin’s lymphoma 1 (2)
  Leukaemia 3 (7)
  Lung 1 (2)
  Lymphoma 7 (15)
  Non-Hodgkin’s 11 (24)
  Oesophagus 1 (2)
  Osteosarcoma 4 (9)
  Prostate 1 (2)
  Missing 1 (2)
Agent Class
 Chemotherapy cyclesb,c 5.2 (1–18)
 Alkylating Mean dose (mg)
  Carboplatin 520.0 2 (4)
  Chlorambucila 1 (2)
  Cisplatin 113.3 5 (11)
  Cyclophosphamide 1148.1 21 (48)
 Anthracyclines
  Doxorubicin 462.1 18 (39)
  Epirubicin 164.0 2 (4)
 Anthracycline combination
  ABVDa 1 (2)
 Antibiotic cytotoxics
  Bleomycin 20.0 1 (2)
 Antimetabolites
  ATRA Azacitidine therapy 100.0 1 (2)
  Adjuvant CTx with carboplatin/gemcitabinea 1 (2)
  Fluorouracil 980.0 3 (7)
  Methotrexate 63.0 5 (11)
  Fludarabine phosphatea 1 (2)
Mitotic Inhibitors
 Amsacrine 140.0 1 (2)
 Docetaxel 145.7 4 (9)
 Etoposide 200.0 1 (2)
 Paclitaxel 429.0 3 (7)
 Vincristinea 12 (26)
Monoclonal Antibodies
 Rituximab 655.0 11 (24)
 Trastuzumab 378.1 7 (15)
 Radiation therapy 28 (61)

a Dose not recorded

b Each patient’s regimen comprised individualised composites and doses of the above cytotoxic agents

c Other drugs taken include: amiloride, amiodarone, amlodipine, atenolol, atorvastatin, bisoprolol, candesartan, carvedilol, cephalexin, cholecalciferol, clonidine, clopidogrel, digoxin, diltiazem, enalapril, enoxaparin, eprosartan, exemestane, frusemide, ibandronate, irbesartan, itraconazole, ivabradine, letrozole, lisinopril, metoprolol, telmisartan/hydrochlorothiazide, nebivolol, olmesartan, oxycodone, pantoprazole, perindopril, prazosin, prednisolone, ramipril, rivaroxaban, simvastatin, sotalol, spironolactone, tamoxifen, tazocin, goserelin zoledronic acid and vancomycin